Vilya, a Seattle, WA-based biotechnology company creating a new class of medicines that precisely target disease biology, expanded its Series A funding to $71M.
The round was led by ARCH Venture Partners with participation from NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. Concurrent with this financing, Menlo Ventures’ Partner Greg Yap joined the Vilya board.
The company intends to use the funds to accelerate advancement of its proprietary computational drug design and development platform and its pipeline of novel macrocycles that precisely target disease biology.
Led by David Baker, Ph.D., CEO Cyrus Harmon, Ph.D., Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. Its proprietary platform, empowered by advanced machine learning and generative AI, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies. It is leveraging the platform to focus on previously difficult-to-drug therapeutic targets.
The company has operations in Seattle and South San Francisco. The leadership team includes Cyrus Harmon, Ph.D., Chief Executive Officer; Katerina Leftheris, Ph.D., Chief Scientific Officer; Patrick Salveson, Ph.D., Co-Founder and Chief Technology Officer; and Inca Dieterich, Ph.D., Co-Founder and Vice President, Business Development.
FinSMEs
05/06/2024